using the Seldinger method. All patients received antiplatelet agents (aspirin, clopidgrel, cilostazol) and heparin. The guidewire was passed into the culprit lesion. Subjects in the Nicorandil Group were then given 2 mg intracoronary nicorandil prior to CAG and an additional intracoronary dose of 2 mg nicorandil before stent implantation. A minimum 2-min interval occurred between the first and second doses of nicorandil to reduce adverse effects. Success of the procedure was defined as greater than 50% increase in internal luminal diameter, less than 30% residual stenosis and Thrombolysis In Myocardial Infarction (TIMI) flow greater than 3. In the Control Group, conventional primary PCI was performed without nicorandil administration.
Analysis of CAG
The composite endpoint consisted of no-reflow, slow flow and ventricular arrhythmia. No-reflow and slow flow were diagnosed when the TIMI flow grade was 2 or lower, despite successful PCI such as balloon angioplasty or stent insertion. TIMI flow grade and TIMI myocardial perfusion grade (MPG) were evaluated by 3 interventional cardiologists prior to completion of the primary PCI.
Clinical Outcomes
In-hospital outcomes were estimated by major adverse cardiac events (MACE), which included death, MI, and target lesion revascularization (TLR). We also analyzed the 30-day clinical outcomes of the 2 groups.
Statistical Analysis
Data are presented as mean ± SD or mean ± SE. For continuous variables, Student t-test was used to assess differences between groups. Nominal variables were analyzed by chi-square test. A value of p<0.05 was considered to be statistically significant.
Results
Of the 73 patients eligible for analysis, 37 and 36 were assigned to the Nicorandil and Control groups, respectively.
Patients' Characteristics
There were no differences between the Nicorandil and Control groups in background factors such as age, sex, hypertension, diabetes mellitus, smoking, family history of ischemic heart disease, time from the onset of symptoms to reperfusion, or medications (Table 1) .
CAG and Procedural Characteristics
There were no differences between the 2 groups in lesion type according to the ACC/AHA lesion classification ( arrhythmia: Nicorandil 0 (0%), Control 2/36 (5.2%); p= 0.037) ( Table 3) .
Clinical Outcomes
There were no differences between the 2 groups in the occurrence of in-hospital MACE. There were no deaths in either group. Acute stent thrombosis occurred in 1 patient in the Nicorandil Group in whom TLR had been performed. The occurrence of 30-day MACE in the Nicorandil and Control groups was not significantly different (Nicorandil Group: 1/37 (2.7%); Control Group: 2/36 (5.2%), p=0.615) ( Table 4) . MACE comprised 1 case of non-ST segment elevation MI and 1 of ST segment elevation MI in the Control Group. These events occurred because of residual stenosis at the distal end of the stent. In addition, subacute stent thrombosis occurred after early discontinuation of antiplatelet agents.
Discussion
In previous studies, the use of intravenous nicorandil in ASTEMI patients improved cardiac function and ischemic preconditioning, and reduced the incidence of no-reflow and slow flow. [1] [2] [3] The mechanisms of action of intravenous nicorandil administration are dilatation of the microvasculature of the coronary artery, antiarrhythmic effects and reduction of reperfusion injury via ATP-sensitive K + channels. Some studies have reported that administration of intravenous nicorandil in ASTEMI reduces myocardium injury and improves heart function, as shown by quantitative thallium SPECT analysis and echocardiography regional wall motion scoring, respectively. 1,8, 9 Ito et al reported that administration of nicorandil in ASTEMI patients reduced no-reflow (Nicorandil Group 15% vs Control Group 33%), ventricular arrhythmia, heart failure and in-hospital mortality. 1 Several factors have been posited to explain these effects. First, suppression of Na/Ca exchange and the reduction of calcium in the myocardium by activation of ATP-sensitive K+ channels may minimize myocardial injury. Second, nicorandil may reduce inflammatory reactions by suppressing neutrophil activation and thereby reducing the resistance of the microvasculature; that is, nicorandil protects the heart by improving coronary blood flow. 10, 11 Finally, nicorandil may decrease heart preload and improve myocardial microcirculation, because it dilates microvessels measuring less than 100 m in diameter. 12 In a recent large-scale study, intravenous nicorandil did not affect the size of the left ventricular ejection fraction 13 and 1 reason that nicorandil treatment did not limit infarct size may have been the dose used. Ishii et al reported that 1 intravenous dose of nicorandil, which was 3-fold higher than that which we used, decreased the infarct size and reduced the rate of cardiovascular death or readmission to hospital for chronic heart failure in 368 patients with acute MI. 14 Sakata et al reported the usefulness of intracoronary nicorandil administration after coronary revascularization for restoring blood flow and functional improvement in patients with acute MI; regional wall motion on 2-dimensional echocardiography improved more significantly in 1 month in the patients who received 2 mg intracoronary nicorandil. 15 Ota et al compared an intracoronary nicorandil group, a combined intravenous and intracoronary group, and a control group in a series of acute MI; the intracoronary nicorandil group had statistically insignificantly reduced reperfusion arrhythmia, no-reflow, slow flow and chest pain (composite endpoint 13% in the intracoronary group vs 33% in the control group). However, they used low-dose intracoronary nicorandil (0.5 mg per dose, maximum dose 1-2 mg). 2 In our study, administration of intracoronary nicorandil in ASTEMI showed results similar to those observed for intravenous nicorandil administration. The frequency of no-reflow, slow flow and ventricular arrhythmia was statistically significantly reduced in the Nicorandil Group (5.4%) when compared with the Control Group (22.2%). These results, which indicate improved microcirculation, are attributed to suppression of both microvasculature spasm and inflammatory reactions. Ishii et al reported that TIMI flow grade and MPG were improved in ASTEMI with administration of intravenous nicorandil. 15 In our study, TIMI flow grade 3 after revascularization in ASTEMI was achieved more frequent (94.0%) in the Nicorandil Group than in the Control Group (75.6%), and MPG 1 was less frequent (0%) in the Nicorandil Group than in the Control Group (13.9%). The improvement of TIMI flow grade and MPG were related to increased blood flow in the myocardium because of dilation of the microvasculature and suppression of spasm. Reduction of no-reflow, slow flow and ventricular arrhythmia are important prognostic factors in ASTEMI, and in previous studies TIMI flow grade and MPG after revascularization were also noted as important prognostic factors in ASTEMI. 14, 15 Reperfusion injury, which may occur after revascularization in ASTEMI and damage the myocardium, is caused by the activity of free radical oxygen species produced by activated leukocytes and complement. 16, 17 Previous studies report that administration of intravenous nicorandil in ASTEMI reduces reperfusion injury after revascularization. In our study, ventricular arrhythmia, as a parameter of reperfusion injury, did not occur in the Nicorandil Group. Administration of intracoronary nicorandil was safe, as shown in previous studies, and generally we used a dose of 2 mg intracoronary nicorandil. However, the maximum dose of intracoronary nicorandil has not yet been established. Intracoronary nicorandil (2 mg per dose) was effective and safe for the management of no-reflow that developed during PCI. 7, 18 Repeated administration of intracoronary nicorandil may elicit adverse effects, but can be conducted safely if an interval of several minutes between doses is observed, presumably because nicorandil dissipates quickly from the myocardium. Low-dose intracoronary nicorandil (0.5 mg per dose) reduced reperfusion arrhythmia, chest pain, no-reflow and slow flow in a previous study, but the effect was statistically insignificant. 2 Therefore, in our study protocol we administered 2 mg intracoronary nicorandil prior to balloon dilatation, waited a minimum of 2 min and then administered an additional 2 mg intracoronary nicorandil before stent implantation. 7 In our study, there was 1 case of acute stent thrombosis in the Nicorandil Group in a patient who had undergone TLR. In another, hematoma occurred at the puncture site of the femoral artery and heparin administration was stopped, but this event was not related to administration of nicorandil.
Glycoprotein IIb-IIIa inhibitor administration improves the clinical outcome of ASTEMI patients who undergo primary PCI by suppressing platelet aggregation, thrombus resolution, and coronary blood flow improvement. 19, 20 Administration of nicorandil with a glycoprotein IIb-IIIa inhibitor may reduce injury to the myocardium and reperfusion injury. In our study, the effects of intracoronary nicorandil were estimated without bias because there was no difference in the frequency of glycoprotein IIb-IIIa in-hibitor administration between the Nicorandil and Control groups.
According to the IONA study, nicorandil treatment improved the long-term prognosis of patients with stable angina, 6, 21 and was effective in treating variant angina by preventing coronary artery spasm. 22 In conclusion, administration of intracoronary nicorandil in ASTEMI patients undergoing PCI was safe, reduced the occurrence of no-reflow, slow reflow, and reperfusion arrhythmia, and improved the MPG and TIMI flow during PCI. Intracoronary nicorandil administration improved the clinical outcomes of patients with ASTEMI by preventing reperfusion injury, improving the microcirculation in the myocardium, ischemic preconditioning and suppressing the development of ventricular arrhythmia. Therefore, administration of intracoronary nicorandil is a potential therapy for protecting the myocardium of patients with ASTEMI.
Study Limitations
The application and generalization of these results are limited because of the small sample size. A multicenter study including a large patient population is needed to confirm the effects and safety of intracoronary nicorandil administration. In addition, the results do not include quantitative analysis of heart function because data from echocardiography and thallium SPECT were not collected in the study.
